{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:44:03Z","timestamp":1785548643673,"version":"3.56.0"},"reference-count":50,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1260714N"],"award-info":[{"award-number":["1260714N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2016,2,17]]},"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>Tumour necrosis factor (TNF) antagonist drug exposure is correlated with clinical, endoscopic and pathophysiological outcomes during induction and maintenance therapy. Measuring drug concentrations is therefore a useful tool when treating to target and optimising therapy. One of the main factors leading to suboptimal drug exposure is the formation of antidrug antibodies (ADAs), due to an immunogenic reaction of the immune system towards the non-self protein. The development of ADA does pose important concerns for drug efficacy and for safety as ADAs have been associated with acute infusion reactions, hypersensitivity reactions and serum sickness. Various assays exist to measure serum drug and ADA concentrations, either offered as a service in a specialised laboratory or commercially available as a kit. It is unclear how the performance of these assays relates to each other, until recently various comparative studies were carried out. The majority of these studies show that indeed a good correlation exists between the assays that measure drug, but that absolute concentrations can differ across tests. This is particularly relevant in clinical practice when a specific threshold or drug concentration range is targeted. For ADA assays, drug sensitivity or the ability of the assay to measure ADA in the presence of drug remains an important issue, especially for drugs with a higher dosing frequency. In addition, standardisation across ADA assays is difficult, making it hard to compare quantitative or semiquantitative (low\/medium\/high) results across assays and across studies.<\/jats:p>","DOI":"10.1136\/flgastro-2016-100692","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T23:24:03Z","timestamp":1457479443000},"page":"236-242","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":50,"title":["Assays for measurement of TNF antagonists in practice"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-0274","authenticated-orcid":false,"given":"Niels","family":"Vande Casteele","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, IBD Center, University of California San Diego, La Jolla, California, USA"},{"name":"Department of Pharmaceutical and Pharmacological Sciences, Therapeutic and Diagnostic Antibodies, KU Leuven\u2014University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,3,8]]},"reference":[{"key":"2025090709134783000_8.4.236.1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.858695"},{"key":"2025090709134783000_8.4.236.2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20178"},{"key":"2025090709134783000_8.4.236.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.4"},{"key":"2025090709134783000_8.4.236.4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305279"},{"key":"2025090709134783000_8.4.236.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.031"},{"key":"2025090709134783000_8.4.236.6","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"2025090709134783000_8.4.236.7","first-page":"2288","article-title":"A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis","volume":"29","author":"den Broeder","year":"2002","journal-title":"J Rheumatol"},{"key":"2025090709134783000_8.4.236.8","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000189901.08684.4b"},{"key":"2025090709134783000_8.4.236.9","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.201533"},{"key":"2025090709134783000_8.4.236.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"2025090709134783000_8.4.236.11","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.236869"},{"key":"2025090709134783000_8.4.236.12","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21839"},{"key":"2025090709134783000_8.4.236.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.10.1133"},{"key":"2025090709134783000_8.4.236.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.07.010"},{"key":"2025090709134783000_8.4.236.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030452"},{"key":"2025090709134783000_8.4.236.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2010.09.005"},{"key":"2025090709134783000_8.4.236.17","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000162"},{"key":"2025090709134783000_8.4.236.18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/apt.12128","article-title":"Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays; authors\u2019 reply","volume":"37","author":"Buurman","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709134783000_8.4.236.19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.004"},{"key":"2025090709134783000_8.4.236.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.009563"},{"key":"2025090709134783000_8.4.236.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2012.06.002"},{"key":"2025090709134783000_8.4.236.22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpba.2013.01.031","article-title":"Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay","volume":"78\u201379","author":"Wang","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"2025090709134783000_8.4.236.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.22214"},{"key":"2025090709134783000_8.4.236.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.21671"},{"key":"2025090709134783000_8.4.236.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2011.08.022"},{"key":"2025090709134783000_8.4.236.26","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000074"},{"key":"2025090709134783000_8.4.236.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203091"},{"key":"2025090709134783000_8.4.236.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203090"},{"issue":"Suppl 1","key":"2025090709134783000_8.4.236.29","first-page":"A602","article-title":"P1572 Point-of-care assays for rapid quantification of infliximab [abstract]","volume":"3","author":"Van Stappen","year":"2015","journal-title":"United European Gastroenterol J"},{"key":"2025090709134783000_8.4.236.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2015.11.087"},{"key":"2025090709134783000_8.4.236.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03207.x"},{"key":"2025090709134783000_8.4.236.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04682.x"},{"key":"2025090709134783000_8.4.236.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2011.07.019"},{"key":"2025090709134783000_8.4.236.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2005.06.014"},{"key":"2025090709134783000_8.4.236.35","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12030"},{"key":"2025090709134783000_8.4.236.36","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.106"},{"key":"2025090709134783000_8.4.236.37","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31828d23c3"},{"key":"2025090709134783000_8.4.236.38","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1515\/cclm-2013-0461","article-title":"Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels","volume":"51","author":"Ruiz-Arg\u00fcello","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"2025090709134783000_8.4.236.39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.dld.2015.10.023","article-title":"Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease","volume":"48","author":"Guiotto","year":"2016","journal-title":"Dig Liver Dis"},{"key":"2025090709134783000_8.4.236.40","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1515\/cclm-2015-0266","article-title":"Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases","volume":"53","author":"Mart\u00edn","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"2025090709134783000_8.4.236.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2015.09.005"},{"key":"2025090709134783000_8.4.236.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90837-8"},{"key":"2025090709134783000_8.4.236.43","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00296-014-3180-2","article-title":"Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis","volume":"35","author":"Hern\u00e1ndez-Fl\u00f3rez","year":"2015","journal-title":"Rheumatol Int"},{"key":"2025090709134783000_8.4.236.44","doi-asserted-by":"crossref","unstructured":"Schmitz EM , van de Kerkhof D , Hamann D , et al . Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med Published Online First: 20 Nov 2015. doi:10.1515\/cclm-2015-0987doi:10.1515\/cclm-2015-0987","DOI":"10.1515\/cclm-2015-0987"},{"key":"2025090709134783000_8.4.236.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2015.12.040"},{"key":"2025090709134783000_8.4.236.46","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2007.089"},{"key":"2025090709134783000_8.4.236.47","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.12"},{"key":"2025090709134783000_8.4.236.48","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305259"},{"key":"2025090709134783000_8.4.236.49","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22910"},{"issue":"1","key":"2025090709134783000_8.4.236.50","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1586\/1744666X.2015.1090312","article-title":"Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13)","volume":"11","author":"Kim","year":"2015","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2016-100692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:13:54Z","timestamp":1757261634000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2016-100692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,8]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,9,11]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1136\/flgastro-2016-100692"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2016-100692","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,8]]}}}